This research study involves pre-operative therapy that is specifically targeted for breast
cancer in individuals with BRCA mutations.
The names of the study drugs involved in this study are:
- Niraparib (Zejula)
- Dostarlimab
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
GlaxoSmithKline Johns Hopkins University Translational Breast Cancer Research Consortium